1. Volume 135, Issue 4, Pages 1130-1141 (October 2008)
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease 
William J. Sandborn, Brian G. Feagan, Richard N. Fedorak, Ellen Scherl, Mark R. Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts 
Gastroenterology 
Volume 135, Issue 4, Pages (October 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Efficacy and safety evaluations included 104 patients in population 1 and 27 patients in population 2.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
Efficacy of ustekinumab. (A) Clinical response over time in the combined ustekinumab and placebo groups in population 1. (B) Clinical response over time in the combined ustekinumab and placebo groups in Population 1 who previously had been treated with infliximab. (C) Odds ratio and 95% confidence intervals for comparing the proportion of patients in clinical response at week 8 in the combined ustekinumab or placebo groups in population 1 stratified by baseline weight, disease characteristics, and Crohn's disease medication history. (D) Median C-reactive protein (CRP) concentrations at week 0 and week 8 in patients treated with subcutaneous or intravenous ustekinumab or placebo in population 1.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions